Fate Therapeutics Inc (NASDAQ:FATE) recently issued its fourth quarter earnings, which more or less was in line with the consensus estimate. The company’s earnings per share stood at ($0.29) as against the market estimate of ($0.27). For the year 2013, the company’s revenue stood at $ 1 million, in line with the analyst forecast. The net loss for the com plete year narrowed to $3.54 per share as against $13.06 loss in the previous year.Fate Therapeutics Inc (NASDAQ:FATE) shares after opening at $11.25 moved to $13.55 on last trade day and at the end of the day closed at $12.28. Company price to sales ratio in past twelve months was calculated as 9.69 and price to cash ratio as 0.81. Fate Therapeutics Inc (NASDAQ:FATE) showed a positive weekly performance of 10.93%.
China Biologic Products, Inc. (NASDAQ:CBPO), a leading fully integrated plasma-based biopharmaceutical company in China , announced its financial results for the fourth quarter and fiscal year 2013. China Biologic Products Inc (NASDAQ:CBPO) shares advanced 6.12% in last trading session and ended the day on $35.04. CBPO return on equity ratio is recorded as 30.30% and its return on assets is 19.20%. China Biologic Products Inc (NASDAQ:CBPO) yearly performance is 29.59%.
Equities researchers at Aegis boosted their price objective on shares of China Cord Blood (NYSE:CO) from $5.00 to $7.00 in a research report issued on Tuesday, AR Network reports. The firm currently has a “buy” rating on the stock. China Cord Blood Corporation (NYSE:CO) shares moved up 5.67% in last trading session and was closed at $4.29while trading in range of $4.06-4.30 – China Cord Blood Corporation (NYSE:CO) year to date (YTD) performance is 6.98%.
EVA Dimensions upgraded shares of Tenet Healthcare Corp (NYSE:THC) from an underweight rating to a hold rating in a research report released on Tuesday morning, StockRatingsNetwork.com reports. Tenet Healthcare Corp (NYSE:THC) weekly performance is%. On last trading day company shares ended up $40.93. Tenet Healthcare Corp (NYSE:THC) distance from 50-day simple moving average (SMA50) is -7.37%. Analysts mean target price for the company is $48.97.